Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 8.23
(0.61%)
CNY 8.23
(0.61%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 434.67 Million CNY | -21.49% |
| 2022 | 553.68 Million CNY | 33.05% |
| 2021 | 416.14 Million CNY | 44.5% |
| 2020 | 287.98 Million CNY | 22.21% |
| 2019 | 235.64 Million CNY | 11.14% |
| 2018 | 212.02 Million CNY | 13.93% |
| 2017 | 186.09 Million CNY | 10.69% |
| 2016 | 168.12 Million CNY | 51.85% |
| 2015 | 110.71 Million CNY | -5.03% |
| 2014 | 116.58 Million CNY | 44.24% |
| 2013 | 80.82 Million CNY | 30.8% |
| 2012 | 61.79 Million CNY | -4.86% |
| 2011 | 64.94 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 428.17 Million CNY | 5.26% |
| 2024 Q1 | 435.84 Million CNY | 0.27% |
| 2024 Q2 | 406.77 Million CNY | -6.67% |
| 2023 Q3 | 430.9 Million CNY | -9.86% |
| 2023 Q4 | 434.67 Million CNY | 0.88% |
| 2023 Q1 | 510.82 Million CNY | -7.74% |
| 2023 FY | 434.67 Million CNY | -21.49% |
| 2023 Q2 | 478.02 Million CNY | -6.42% |
| 2022 Q4 | 553.68 Million CNY | 0.61% |
| 2022 Q3 | 550.31 Million CNY | 8.9% |
| 2022 Q2 | 505.33 Million CNY | 12.72% |
| 2022 FY | 553.68 Million CNY | 33.05% |
| 2022 Q1 | 448.29 Million CNY | 7.72% |
| 2021 Q1 | 254.23 Million CNY | -11.72% |
| 2021 Q3 | 354.71 Million CNY | 13.55% |
| 2021 Q4 | 416.14 Million CNY | 17.32% |
| 2021 FY | 416.14 Million CNY | 44.5% |
| 2021 Q2 | 312.38 Million CNY | 22.87% |
| 2020 Q1 | 222.6 Million CNY | -5.53% |
| 2020 FY | 287.98 Million CNY | 22.21% |
| 2020 Q4 | 287.98 Million CNY | 20.19% |
| 2020 Q3 | 239.61 Million CNY | 16.39% |
| 2020 Q2 | 205.86 Million CNY | -7.52% |
| 2019 Q2 | 204.64 Million CNY | 9.21% |
| 2019 Q1 | 187.38 Million CNY | -11.62% |
| 2019 FY | 235.64 Million CNY | 11.14% |
| 2019 Q4 | 235.64 Million CNY | 10.04% |
| 2019 Q3 | 214.14 Million CNY | 4.64% |
| 2018 Q3 | 222.3 Million CNY | 11.08% |
| 2018 Q2 | 200.13 Million CNY | 11.47% |
| 2018 Q1 | 179.54 Million CNY | -3.52% |
| 2018 FY | 212.02 Million CNY | 13.93% |
| 2018 Q4 | 212.02 Million CNY | -4.62% |
| 2017 Q3 | 154.08 Million CNY | 13.98% |
| 2017 Q4 | 186.09 Million CNY | 20.78% |
| 2017 Q2 | 135.17 Million CNY | -9.49% |
| 2017 Q1 | 149.34 Million CNY | -11.17% |
| 2017 FY | 186.09 Million CNY | 10.69% |
| 2016 Q2 | 127.23 Million CNY | 11.57% |
| 2016 Q4 | 168.12 Million CNY | 33.33% |
| 2016 Q3 | 126.09 Million CNY | -0.89% |
| 2016 Q1 | 114.03 Million CNY | 3.0% |
| 2016 FY | 168.12 Million CNY | 51.85% |
| 2015 Q3 | 95.62 Million CNY | 4.16% |
| 2015 FY | 110.71 Million CNY | -5.03% |
| 2015 Q4 | 110.71 Million CNY | 15.78% |
| 2015 Q1 | 99.04 Million CNY | -15.04% |
| 2015 Q2 | 91.8 Million CNY | -7.31% |
| 2014 Q4 | 116.58 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 116.58 Million CNY | 44.24% |
| 2013 FY | 80.82 Million CNY | 30.8% |
| 2012 FY | 61.79 Million CNY | -4.86% |
| 2011 FY | 64.94 Million CNY | 0.0% |